1. Spain Stocks

  2. •

    Health technology

  3. •

    Pharmaceuticals: other
Pharma Mar SA

Pharma Mar SA

77.95
EUR
-3.85
(-4.71%)
4.58EPS
15.93P/E
1.26BMarket Cap
Nov 04Next Earn
2013 Y
2014 Y
2015 Y
2016 Y
2017 Y
2018 Y
2019 Y
2020 Y
2021 Y
2022 Y
2023 Y
2024 Y
2025 Y
TTM
Revenue per Share
7.65
9.5
10.49
9.84
8.64
5.91
4.65
14.76
12.72
10.88
8.84
9.97
12.7
15.97
Basic EPS, GAAP
0.62
0.72
0.36
-1.31
-1.45
-0.3
-0.62
7.5
5.14
2.73
0.06
1.49
4.3
4.58
Free Cash Flow per Basic Share
1.01
1.24
0.6
-0.46
-0.08
-0.91
-1.53
15.08
0.99
1.63
-1.64
-0.54
2.51
2.86
Dividend per Share
- -
- -
- -
- -
- -
- -
- -
0.48
0.6
0.65
0.65
0.65
0.8
- -
Book Value per Share
2.9
3.5
4.17
2.84
1.46
1.16
0.61
5.67
9.88
12.31
10.97
11.86
14.51
14.48
Tangible Book Value per Share
1.53
1.92
2.58
1.35
0.22
0.12
0.29
5.46
9.7
12.17
10.86
11.8
14.3
14.24
Basic Weighted Avg Shares
18
18
18
18
18
18
18
18
18
18
18
18
17
17
Sales/Revenue/Turnover
140
174
193
181
159
109
86
270
230
196
158
175
221
277
Operating Margin (%)
13.49
11.63
5.86
-10.34
-12.3
-14.74
-20.36
57.86
40.18
22.63
-2.48
3.44
27.08
22.44
Depreciation Expense
5
5
6
7
7
6
8
7
6
6
6
7
8
8
Net Income, GAAP
11
13
7
-24
-27
-6
-11
137
93
49
1
26
75
79
Effective Tax Rate (%)
14.2
9.01
- -
- -
- -
- -
- -
5.73
2.39
- -
- -
- -
- -
- -
Profit Margin (%)
8.06
7.54
3.42
-13.31
-16.84
-5.09
-13.26
50.85
40.4
25.14
0.72
14.94
33.87
28.68
Working Capital
22
19
42
34
10
3
-10
151
209
178
157
168
190
183
LT Debt
53
47
65
68
74
65
55
40
35
28
29
41
37
34
Total Equity
49
60
73
48
23
17
7
103
178
223
193
208
252
251
Return on Invested Capital (%)
10.89
12.5
- -
- -
- -
- -
- -
116.55
46.77
- -
- -
- -
- -
- -
Return on Capital (%)
11.39
12.84
- -
- -
- -
- -
- -
110.85
49.74
- -
- -
- -
- -
- -
Return on Common Equity (%)
23.7
22.4
9.36
-37.27
-67.52
-22.95
-69.5
240.61
66.18
24.62
0.55
13
32.59
35.47

Capital Structure

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
ST Debt
13
13
12
LT Borrowings
36
33
32
LT Finance Leases
1
1
1
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
17
17
17
Market Capitalization
1,308
1,500
1,264

Working Capital

EUR

•

in mil. unless spec.
Dec'25
Mar'26
Jun'26
Total Current Assets
283
273
281
Cash, Cash Equivalents & STI
167
168
169
Accounts Receivable, Net
39
40
48
Inventories
51
53
50
Total Current Liabilities
94
89
98
Payables & Accruals
- -
- -
- -
ST Debt
13
13
12
Deferred Revenue
- -
- -
- -

Growth Rates

EUR

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
122.4%
22.77%
20.86%
Free Cash Flow
-107.49%
-171.51%
-561.36%
Net Income, GAAP
47.34%
441.57%
187.03%
Sales/Revenue/Turnover
13.18%
-2.34%
26.61%
Total Cash Common Dividend
- -
10.14%
22.15%

Quarterly Revenue

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
38
43
46
94
175
2025
39
56
- -
128
221
2026
43
50
- -
- -
- -

Quarterly Earnings Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
0.13
0.07
0.22
1.29
1.49
2025
-0.23
1.34
- -
3.2
4.3
2026
0.09
-0.06
- -
- -
- -

Quarterly Dividends Per Share

EUR

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2024
- -
- -
- -
- -
0.65
2025
- -
- -
- -
- -
0.8
2026
- -
- -
- -
- -
- -

Company Description

Company Profile APIChatGPT
CEO
José Maria Fernández de Sousa-Faro
Full Time Employees
505
Sector
Health technology
Industry
Pharmaceuticals: other
Address
Avenida de los Reyes, 1 Colmenar Viejo Spain 28770
IPO Date
Nov 2, 2015
Website
pharmamar.com
Similar Companies
Cipla Ltd (NSE:CIPLA)
Aurobindo Pharma Ltd (NSE:AUROPHARMA)
Lupin Limited (NSE:LUPIN)
Granules India Limited (NSE:GRANULES)
Revolution Medicines, Inc. (NASDAQ:RVMD)
Egyptian International Pharmaceutical Industries Co. (EGX:PHAR)
Business
Pharma Mar Pharma Mar, S.A. (PHM.MC) is a Spain-based integrated biopharmaceutical company focused on the research, development, production, and commercialization of antitumor drugs derived from marine organisms, primarily targeting oncology indications; it operates through three main business segments including Oncology, Diagnostics, and RNA interference, with additional activities in clinical-stage programs and consumer chemicals. The company markets approved products such as Yondelis (trabectedin), indicated for advanced soft tissue sarcoma and relapsed platinum-sensitive ovarian cancer, and Zepzelca (lurbinectedin), approved for metastatic small cell lung cancer with disease progression on or after platinum-based chemotherapy; its pipeline includes investigational candidates like Aplidin (plitidepsin) and others such as PM184 and PM14 in development for various cancers, alongside diagnostic kits for molecular testing and RNAi-based therapies that silence gene expression for therapeutic applications. Founded in 1986 and headquartered in Colmenar Viejo near Madrid, Spain, Pharma Mar conducts global operations with subsidiaries like Genomica for diagnostics and Sylentis for RNAi therapeutics, serving markets in Europe, the United States, Latin America, and beyond through licensing partnerships. Recent developments include partner Immedica Pharma AB securing full commercialization approval for one of its products, Adium Pharma obtaining conditional marketing authorization for Zepzelca in Argentina in 2025 to expand its global footprint, and the company reporting net income of €15.3 million for the nine months ended September 30, 2025, reflecting improved financial performance compared to the prior year alongside ongoing treasury share acquisitions and pipeline advancements.

Company News

Company News APIChatGPT

  • seekingalpha.com

    Pharma Mar, S.A. (PHMMF) Q2 2026 Earnings Call Transcript

  • seekingalpha.com

    Pharma Mar, S.A. (PHMMF) Shareholder/Analyst Call Transcript

  • globenewswire.com

    PMV Pharmaceuticals Announces Board Chair Transition

  • seekingalpha.com

    Pharma Mar, S.A. (PHMMF) Q4 2025 Earnings Call Transcript

  • defenseworld.net

    Head-To-Head Analysis: Pharma Mar (OTCMKTS:PHMMF) vs. Imunon (NASDAQ:IMNN)

  • seekingalpha.com

    Pharma Mar, S.A. (PHMMF) Q4 2022 Earnings Call Transcript